Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations

Yusuke Ogoshi, Kazuhiko Shien, Takahiro Yoshioka, Hidejiro Torigoe, Hiroki Sato, Masakiyo Sakaguchi, Shuta Tomida, Kei Namba, Eisuke Kurihara, Yuta Takahashi, Ken Suzawa, Hiromasa Yamamoto, Junichi Sou, Shinichi Toyooka

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Human epidermal growth factor receptor 2 (HER2) is a member of the ErbB family of receptor tyrosine kinases. Numerous studies have reported the amplification and overexpression of HER2 in several types of cancer, including non-small cell lung cancer (NSCLC). However, the benefits of HER2-targeted therapy have not been fully established. In the present study, the anti-tumor effect of neratinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), against NSCLC cells harboring HER2 alterations was investigated. The sensitivity of normal bronchial epithelial cells (BEAS-2B) ectopically overexpressing wild-type or mutant HER2 to neratinib was assessed. Furthermore, the anti-tumor activity of neratinib in several NSCLC cell lines harboring HER2 alterations was determined in vitro and in vivo, and the association between their genetic alterations and sensitivity to neratinib treatment was investigated. BEAS-2B cells ectopically overexpressing wild-type HER2 or mutants (A775insYVMA, G776VC, G776LC, P780insGSP, V659E, G660D and S310F) exhibited constitutive autophosphorylation of HER2, as determined by western blotting. While these BEAS-2B cells were sensitive to neratinib, they were insensitive to erlotinib, a first-generation epidermal growth factor receptor-TKI. Neratinib also exerted anti-proliferative effects on HER2-altered (H2170, Calu-3 and H1781) NSCLC cell lines. Neratinib was also demonstrated to exert strong tumor growth inhibitory activity in mouse xenograft models using HER2-altered lung cancer cells. The results of the present study strongly suggest that neratinib has potential as a promising therapeutic option for the treatment of HER2-altered NSCLC.

Original languageEnglish
Pages (from-to)2729-2736
Number of pages8
JournalOncology Letters
Volume17
Issue number3
DOIs
Publication statusPublished - Mar 1 2019

Fingerprint

Oncogenes
Lung Neoplasms
Non-Small Cell Lung Carcinoma
Neoplasms
Protein-Tyrosine Kinases
N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide
human ERBB2 protein
Cell Line
Epidermal Growth Factor Receptor
Heterografts
Western Blotting
Epithelial Cells

Keywords

  • HER2
  • Lung cancer
  • Neratinib
  • NSCLC
  • Pan-HER tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations. / Ogoshi, Yusuke; Shien, Kazuhiko; Yoshioka, Takahiro; Torigoe, Hidejiro; Sato, Hiroki; Sakaguchi, Masakiyo; Tomida, Shuta; Namba, Kei; Kurihara, Eisuke; Takahashi, Yuta; Suzawa, Ken; Yamamoto, Hiromasa; Sou, Junichi; Toyooka, Shinichi.

In: Oncology Letters, Vol. 17, No. 3, 01.03.2019, p. 2729-2736.

Research output: Contribution to journalArticle

Ogoshi, Y, Shien, K, Yoshioka, T, Torigoe, H, Sato, H, Sakaguchi, M, Tomida, S, Namba, K, Kurihara, E, Takahashi, Y, Suzawa, K, Yamamoto, H, Sou, J & Toyooka, S 2019, 'Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations', Oncology Letters, vol. 17, no. 3, pp. 2729-2736. https://doi.org/10.3892/ol.2019.9908
Ogoshi, Yusuke ; Shien, Kazuhiko ; Yoshioka, Takahiro ; Torigoe, Hidejiro ; Sato, Hiroki ; Sakaguchi, Masakiyo ; Tomida, Shuta ; Namba, Kei ; Kurihara, Eisuke ; Takahashi, Yuta ; Suzawa, Ken ; Yamamoto, Hiromasa ; Sou, Junichi ; Toyooka, Shinichi. / Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations. In: Oncology Letters. 2019 ; Vol. 17, No. 3. pp. 2729-2736.
@article{48082076e1444946b373935685cc8e86,
title = "Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations",
abstract = "Human epidermal growth factor receptor 2 (HER2) is a member of the ErbB family of receptor tyrosine kinases. Numerous studies have reported the amplification and overexpression of HER2 in several types of cancer, including non-small cell lung cancer (NSCLC). However, the benefits of HER2-targeted therapy have not been fully established. In the present study, the anti-tumor effect of neratinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), against NSCLC cells harboring HER2 alterations was investigated. The sensitivity of normal bronchial epithelial cells (BEAS-2B) ectopically overexpressing wild-type or mutant HER2 to neratinib was assessed. Furthermore, the anti-tumor activity of neratinib in several NSCLC cell lines harboring HER2 alterations was determined in vitro and in vivo, and the association between their genetic alterations and sensitivity to neratinib treatment was investigated. BEAS-2B cells ectopically overexpressing wild-type HER2 or mutants (A775insYVMA, G776VC, G776LC, P780insGSP, V659E, G660D and S310F) exhibited constitutive autophosphorylation of HER2, as determined by western blotting. While these BEAS-2B cells were sensitive to neratinib, they were insensitive to erlotinib, a first-generation epidermal growth factor receptor-TKI. Neratinib also exerted anti-proliferative effects on HER2-altered (H2170, Calu-3 and H1781) NSCLC cell lines. Neratinib was also demonstrated to exert strong tumor growth inhibitory activity in mouse xenograft models using HER2-altered lung cancer cells. The results of the present study strongly suggest that neratinib has potential as a promising therapeutic option for the treatment of HER2-altered NSCLC.",
keywords = "HER2, Lung cancer, Neratinib, NSCLC, Pan-HER tyrosine kinase inhibitor",
author = "Yusuke Ogoshi and Kazuhiko Shien and Takahiro Yoshioka and Hidejiro Torigoe and Hiroki Sato and Masakiyo Sakaguchi and Shuta Tomida and Kei Namba and Eisuke Kurihara and Yuta Takahashi and Ken Suzawa and Hiromasa Yamamoto and Junichi Sou and Shinichi Toyooka",
year = "2019",
month = "3",
day = "1",
doi = "10.3892/ol.2019.9908",
language = "English",
volume = "17",
pages = "2729--2736",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations

AU - Ogoshi, Yusuke

AU - Shien, Kazuhiko

AU - Yoshioka, Takahiro

AU - Torigoe, Hidejiro

AU - Sato, Hiroki

AU - Sakaguchi, Masakiyo

AU - Tomida, Shuta

AU - Namba, Kei

AU - Kurihara, Eisuke

AU - Takahashi, Yuta

AU - Suzawa, Ken

AU - Yamamoto, Hiromasa

AU - Sou, Junichi

AU - Toyooka, Shinichi

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Human epidermal growth factor receptor 2 (HER2) is a member of the ErbB family of receptor tyrosine kinases. Numerous studies have reported the amplification and overexpression of HER2 in several types of cancer, including non-small cell lung cancer (NSCLC). However, the benefits of HER2-targeted therapy have not been fully established. In the present study, the anti-tumor effect of neratinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), against NSCLC cells harboring HER2 alterations was investigated. The sensitivity of normal bronchial epithelial cells (BEAS-2B) ectopically overexpressing wild-type or mutant HER2 to neratinib was assessed. Furthermore, the anti-tumor activity of neratinib in several NSCLC cell lines harboring HER2 alterations was determined in vitro and in vivo, and the association between their genetic alterations and sensitivity to neratinib treatment was investigated. BEAS-2B cells ectopically overexpressing wild-type HER2 or mutants (A775insYVMA, G776VC, G776LC, P780insGSP, V659E, G660D and S310F) exhibited constitutive autophosphorylation of HER2, as determined by western blotting. While these BEAS-2B cells were sensitive to neratinib, they were insensitive to erlotinib, a first-generation epidermal growth factor receptor-TKI. Neratinib also exerted anti-proliferative effects on HER2-altered (H2170, Calu-3 and H1781) NSCLC cell lines. Neratinib was also demonstrated to exert strong tumor growth inhibitory activity in mouse xenograft models using HER2-altered lung cancer cells. The results of the present study strongly suggest that neratinib has potential as a promising therapeutic option for the treatment of HER2-altered NSCLC.

AB - Human epidermal growth factor receptor 2 (HER2) is a member of the ErbB family of receptor tyrosine kinases. Numerous studies have reported the amplification and overexpression of HER2 in several types of cancer, including non-small cell lung cancer (NSCLC). However, the benefits of HER2-targeted therapy have not been fully established. In the present study, the anti-tumor effect of neratinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), against NSCLC cells harboring HER2 alterations was investigated. The sensitivity of normal bronchial epithelial cells (BEAS-2B) ectopically overexpressing wild-type or mutant HER2 to neratinib was assessed. Furthermore, the anti-tumor activity of neratinib in several NSCLC cell lines harboring HER2 alterations was determined in vitro and in vivo, and the association between their genetic alterations and sensitivity to neratinib treatment was investigated. BEAS-2B cells ectopically overexpressing wild-type HER2 or mutants (A775insYVMA, G776VC, G776LC, P780insGSP, V659E, G660D and S310F) exhibited constitutive autophosphorylation of HER2, as determined by western blotting. While these BEAS-2B cells were sensitive to neratinib, they were insensitive to erlotinib, a first-generation epidermal growth factor receptor-TKI. Neratinib also exerted anti-proliferative effects on HER2-altered (H2170, Calu-3 and H1781) NSCLC cell lines. Neratinib was also demonstrated to exert strong tumor growth inhibitory activity in mouse xenograft models using HER2-altered lung cancer cells. The results of the present study strongly suggest that neratinib has potential as a promising therapeutic option for the treatment of HER2-altered NSCLC.

KW - HER2

KW - Lung cancer

KW - Neratinib

KW - NSCLC

KW - Pan-HER tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85062066500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062066500&partnerID=8YFLogxK

U2 - 10.3892/ol.2019.9908

DO - 10.3892/ol.2019.9908

M3 - Article

AN - SCOPUS:85062066500

VL - 17

SP - 2729

EP - 2736

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 3

ER -